Zealand Pharma A/S (DK0060257814) — research page
DK · dk-cm-kg/XCSE/DK0060257814 · as of 2026-11-06
Identity and listing
The issuer is Zealand Pharma A/S, listed on Nasdaq Copenhagen under ticker DK0060257814, with ISIN DK0060257814 and LEI 549300ITBB1ULBL4CZ12. Its security type, segment, sector and jurisdiction are not on the record. Its listing status is listed, not halted.
| field | value | source · read date |
|---|---|---|
| name | Zealand Pharma A/S | source · 2026-11-06 |
| exchange | Nasdaq Copenhagen | source · 2026-11-06 |
| ticker | DK0060257814 | source · 2026-11-06 |
| ISIN | DK0060257814 | source · 2026-11-06 |
| LEI | 549300ITBB1ULBL4CZ12 | source · 2026-11-09 |
| security type | not on the record | |
| segment | not on the record | |
| sector | not on the record | |
| jurisdiction | not on the record | |
| status | listed, not halted | source · 2026-11-09 |
The disclosure read
The record holds 59 filings across 49 filing days in the window from 2025-11-06 to 2026-11-06. The median gap between filing days is 6.0 days. The latest filing is dated 2026-10-07, 30 days before the record date of 2026-11-06, and is of type Inside information. The exchange median cadence gap is 8.0 days, the exchange median filings count is 25, and the exchange median latency is 4.0 days across 119 issuers. The sector median is not on the record.
| filings | median gap between filing days | days from latest filing to as-of | |
|---|---|---|---|
| this issuer | 59 | 6 | 30 |
| exchange median: Nasdaq Copenhagen (119 issuers) | 25 | 8 | 4 |
| date | type | category | filing |
|---|---|---|---|
| 2026-10-07 | Inside information | Inside information | Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes |
| 2026-10-05 | Changes in company's own shares | Changes in company's own shares | Zealand Pharma - Completion of share buy-back program and related transactions (week 40 and 41, 2026) |
| 2026-10-01 | Inside information | Inside information | Zealand Pharma announces Boehringer Ingelheim's survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes |
| 2026-09-30 | Total number of voting rights and capital | Total number of voting rights and capital | Total number of shares and voting rights in Zealand Pharma as of September 30, 2026 |
| 2026-09-28 | Changes in company's own shares | Changes in company's own shares | Zealand Pharma - Transactions related to share buy-back program (week 39, 2026) |
window 2025-11-06 to 2026-11-06 · the node's disclosure lines, as get_filings serves them
Auditor
The auditor of record and its location are not on the record. Auditor changes are not on the record, as this register has no lifecycle type map yet.
Events and halts
Listing, delisting, name change, domicile change and segment move are not on the record, as this register has no lifecycle type map yet. The halt flag is not set, and the issuer is listed, not halted.
Orderability
The outcome is not determinable, because the chapter's orderability section carries no client categories to name. The rule version is acm-68000/dk/mifid-ii-product-governance/r1, with the chapter as of 2026-11-04.
rule acm-68000/dk/mifid-ii-product-governance/r1 · chapter as of 2026-11-04 · the full outcome: get_orderability
Coverage
No research houses were found on the issuer's investor-relations pages read.
Open research
No openly published research notes were found on the record.
Licensed
Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.
| licensor | entitlement | title | date | source |
|---|---|---|---|---|
| none loaded |
As-of depth
The market's vintage is not sealed. No issuer years are sealed, and the market's earliest sealed date and the live record start date are not on the record.
Sources
6 source pages are named on this page; every value above carries its own source page and read date in the numbers.
- 10.1
- https://firds.esma.europa.eu/firds/ (identity.exchange)
- 10.2
- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)
- 10.3
- https://mcp.dk-cm-kg.ai/events/XCSE/DK0060257814 (the disclosure lines)
- 10.4
- https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=exchangeNewsFilterCPH|FirstNorthInformationCPH (the halt flag)
- 10.5
- https://dk.eu-cm-kg.ai/book/aio.json (the orderability chapter)
- 10.6
- https://mcp.dk-cm-kg.ai/record/XCSE/DK0060257814 (the record)
Read it by agent
The same page, signed and receipted: get_research at https://mcp.getresearch.ai/mcp with {"isin":"DK0060257814"}. Twins: .md · .json. Written: Claude through the platform account, Haiku class; one pass; checked against the numbers. Page hash sha256:41075b7e4e515c5c.